Despite challenges, private practice has many rewards, such as more autonomy, says Tien-I Karleen Su, MD, FACR, chair of the ACR’s Community Practice Council.
Current knowledge of receptor-ligand interactions, cell signaling, and transcriptional regulation derive from studies of type I interferon. The design of novel therapeutics is informed by the advances in investigation of type I interferon, with the potential for important impacts on patient management.
In this episode, Dr. Kumar discusses brief, everyday exchanges that send denigrating messages to certain individuals because of their group membership.
Community practice rheumatology brings with it certain challenges, but it also offers rewards, such as autonomy and the capacity to develop deep relationships with patients. Three rheumatologists discuss the challenges and rewards of private practice.
The Feb. 21 cyberattack on Change Healthcare, the clearinghouse vendor that connects providers with insurance payers, including Medicare, has caused unprecedented challenges and had a critical financial impact on payments to providers nationwide. UnitedHealthcare Group (UHG), the parent company of Change, confirmed on March 8 that it is making significant progress to restore all systems….
Gwenesta B. Melton, MD, wears many hats as a rheumatologist, teacher and champion for advocacy and collaboration. She has been involved with the ASC for more than a decade.
The newest funding package reduces the latest cut to Medicare reimbursement from 3.4% to 1.68%. Although rheumatologists are faring better under Medicare in 2024, broader reforms remain the ACR’s highest priority regarding Medicare payments to physicians.
The Centers for Medicare & Medicaid Services updated recent regulations to clarify some points about remote physiologic monitoring (RPM) and remote therapeutic monitoring (RTM) services for key areas.
In an election year, it is critical that the ACR’s non-partisan political action committee be well positioned to support our congressional champions. Learn more about RheumPAC and its role in the ACR’s advocacy efforts.
The Insurance Subcommittee is working to address coverage and reimbursement challenges facing rheumatology practices, including issues related to biosimilar use, in-office treatments and the new G2211 code.